Hiroshi Sakai
Hiroshima University · 465 works · 13,666 citations · h-index 44
Top works
- Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
- First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
- Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
- Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial
- Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial
- A cross-validation of the European organization for research and treatment of cancer QLQ-C30 (EORTC QLQ-C30) for Japanese with Lung Cancer
- Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
- Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
- Relationship between changes in length and force in in vitro reconstructed anterior cruciate ligament
- Relationship Between Renal Function and Plasma Brain Natriuretic Peptide in Patients With Heart Failure
- Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer
- First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial
- Uveal effusion in primary angle-closure glaucoma
- First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update
- Plasma Glutathione Peroxidase Deficiency Caused by Renal Dysfunction
- Prevalence of Primary Angle Closure and Primary Angle-Closure Glaucoma in a Southwestern Rural Population of Japan
- Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer
- Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA.
- Anticoagulation Therapy for Venous Thromboembolism in the Real World ― From the COMMAND VTE Registry ―
- Characterization of murine complement receptor type 2 and its immunological cross-reactivity with type 1 receptor